Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Review ArticlePractice

Buprenorphine

New treatment of opioid addiction in primary care

Meldon Kahan, Anita Srivastava, Alice Ordean and Sharon Cirone
Canadian Family Physician March 2011, 57 (3) 281-289;
Meldon Kahan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kahanm@stjoe.on.ca
Anita Srivastava
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alice Ordean
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharon Cirone
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Abstract

Objective To review the use of buprenorphine for opioid-addicted patients in primary care.

Quality of evidence The MEDLINE database was searched for literature on buprenorphine from 1980 to 2009. Controlled trials, meta-analyses, and large observational studies were reviewed.

Main message Buprenorphine is a partial opioid agonist that relieves opioid withdrawal symptoms and cravings for 24 hours or longer. Buprenorphine has a much lower risk of overdose than methadone and is preferred for patients at high risk of methadone toxicity, those who might need shorter-term maintenance therapy, and those with limited access to methadone treatment. The initial dose should be given only after the patient is in withdrawal. The therapeutic dose range for most patients is 8 to 16 mg daily. It should be dispensed daily by the pharmacist with gradual introduction of take-home doses. Take-home doses should be introduced more slowly for patients at higher risk of abuse and diversion (eg, injection drug users). Patients who fail buprenorphine treatment should be referred for methadone- or abstinence-based treatment.

Conclusion Buprenorphine is an effective treatment of opioid addiction and can be safely prescribed by primary care physicians.

North America has witnessed a marked increase in prescription opioid misuse and addiction in the past 10 years, accompanied by increases in overdose deaths.1–3 These increases parallel the rise in the use of controlled-release opioids for chronic pain.4 Despite the great need for opioid addiction treatment, access to methadone treatment is limited; only an estimated 23% of opioid-addicted patients in Canada were taking methadone in 2003, a lower proportion than in Western European countries.5

Treatment access would expand considerably if family physicians began to prescribe buprenorphine, a safe and effective alternative to methadone. In France, family physicians prescribe buprenorphine to 65 000 patients, whereas specialized clinics prescribe methadone to only 6000 to 7000 patients.6 Cohort studies and controlled trials have demonstrated that buprenorphine treatment of opioid addiction is safe and effective when prescribed by primary care physicians in community settings.7–21

Although methadone might have a higher treatment retention rate than buprenorphine,18,22,23 buprenorphine is also a very effective treatment of opioid addiction. Also, buprenorphine might be more effective in patients addicted to prescription opioids than it is in those addicted to heroin24 (which might reflect the greater social stability of oral prescription users compared with heroin users); it could, therefore, be very useful to family doctors. The primary advantage of buprenorphine is its safety: large observational studies have found that buprenorphine has a much lower risk of overdose than methadone,6,25 and this makes it safer for use in primary care.26 An analysis of French overdose deaths between 1995 and 1998 found an average annual death rate of 0.47% for patients taking methadone, compared with 0.05% for buprenorphine.27

Buprenorphine is a safe and effective alternative to methadone treatment of opioid dependence. This article reviews the use of buprenorphine in primary care.

Quality of evidence

MEDLINE was searched from 1980 to 2009, using the terms buprenorphine, methadone, addiction, opioid, primary care, and overdose. Randomized controlled trials, cohort studies, and large observational studies were included. We also considered guidelines from other jurisdictions as well as our collective clinical experience.

Clinical features of prescription opioid addiction

Typically, patients addicted to prescription opioids are young (younger than 45 years of age) and have a history of addiction to opioids, alcohol, cocaine, or other drugs. They often have an underlying anxiety or mood disorder, such as posttraumatic stress disorder.

If they are being prescribed opioids for underlying pain conditions, patients addicted to opioids tend to be taking doses well beyond what would usually be required (Table 1). They might attempt to maximize the opioid’s psychoactive effect and avoid withdrawal symptoms by binging on the opioid, crushing or injecting oral tablets, and accessing opioids from multiple physicians or the street. If their personal physicians are the main source of the opioid, they frequently request higher doses and early refills. They often report withdrawal symptoms and difficulties at home or at work.

View this table:
  • View inline
  • View popup
Table 1.

Clinical features of prescription opioid addiction

Opioid-addicted patients with concurrent pain sometimes experience withdrawal-mediated pain at the end of a dosing interval. Withdrawal–mediated pain is intense and is accompanied by myalgia, dysphoria, drug craving, and other withdrawal symptoms. In contrast, pain that is unrelated to withdrawal increases gradually as the analgesic wears off and is not accompanied by dysphoria or myalgia.

Case

Mr H. is a 36-year-old man who injured his back 3 years ago while lifting heavy machinery at work. He has had chronic low back pain since then and has been unemployed and supporting himself through Workplace Safety and Insurance Board benefits. He has had trouble sleeping and has been depressed and anxious since he stopped working. He was initially started on acetaminophen-oxycodone (325 mg/5 mg) tablets, 1 tablet 4 times daily, but this was only partially helping his pain and he was switched to 10 mg of sustained-release oxycodone 4 times daily. His dose has been escalating over the past 2 years and he is now taking 80 mg of sustained-release oxycodone 4 times daily. He often asks his doctor’s receptionist to fit him in for early renewal of his medications.

Role of buprenorphine in primary care

Most family physicians will prescribe buprenorphine primarily for opioid-dependent patients who are already in their practices. Prescribing opioids to an addicted patient can be frustrating and time-consuming, and (in our experience) it usually has poor outcomes. In contrast, patients’ mood, functioning, pain, and withdrawal symptoms usually improve with buprenorphine, making the patient-doctor interaction more satisfying and therapeutic. Physicians should refer patients who do not respond to buprenorphine treatment to a specialized methadone program. This stepped-care approach exposes patients to the safest drug first (buprenorphine), transferring them to another drug if necessary.28

Case continued

Mr H. denies injecting the oxycodone, but admits that he often crushes the tablets and has on 1 occasion snorted a crushed tablet. He finds that he needs more and more oxycodone to get the same pain relief; his pain remains at 5 or 6 out of 10. When the oxycodone wears off, he experiences marked worsening of the pain (“12 out of 10”), along with depressed mood, myalgia, sweating, and diarrhea. He feels as though he needs to take the oxycodone just to feel “normal.”

Indications for buprenorphine treatment

Table 2 outlines the indications for buprenorphine, methadone, and detoxification. Buprenorphine maintenance should be considered over detoxification or methadone in patients who meet 1 or more of the following criteria:

View this table:
  • View inline
  • View popup
Table 2.

Indications for detoxification, buprenorphine, or methadone

Quickly relapsed after a trial of detoxification. Such quick relapse suggests that the patient needs treatment with either methadone or buprenorphine.

Adolescents, young adults, and others who might not need long-term opioid agonist treatment. Buprenorphine has a milder withdrawal syndrome and might be easier to discontinue than methadone.29 For this reason it could be the first choice for patients who have good prognoses and might be able to successfully taper off buprenorphine after several months.

At higher risk of methadone toxicity. Higher-risk patients include older patients, those taking benzodiazepines or other sedating drugs, heavy drinkers, patients with chronic obstructive pulmonary disease or other respiratory illnesses, and patients with lower tolerance to opioids (eg, taking weak opioids, such as codeine, or nondaily doses of oral opioids).

Socially stable oral prescription opioid users. For such patients, methadone take-home restrictions will be problematic (eg, patients with full-time family or work responsibilities or limited access to transportation).

Limited or no access to methadone. Patients living, for example, in rural or northern communities might have limited or no access to methadone treatment.

Pregnant patients with no access to methadone treatment. Methadone maintenance is currently the standard of care for opioid addiction during pregnancy. However, buprenorphine could be an alternative to methadone maintenance treatment in pregnancy, especially for patients who do not have access to methadone (eg, lack of services in a certain geographical location). Buprenorphine-naloxone in combination is contraindicated in pregnancy because the safety of naloxone in pregnancy has not been established. However, buprenorphine without naloxone has been shown to be safe and effective in pregnancy.30,31 Buprenorphine should only be prescribed for pregnant women after a detailed discussion of risks, benefits, and treatment options. Buprenorphine without naloxone can be obtained on a case-by-case basis through Health Canada’s Special Access Programme (www.hc-sc.gc.ca/dhp-mps/acces/drugs-drogues/index_e.html).

Case continued

Mr H. has tried to taper off his oxycodone multiple times without success. Each time he has relapsed after a few days. He does not want to go into a formal withdrawal management program, and he lives 2 hours away from the nearest methadone treatment centre.

Pharmacology

Table 3 outlines the pharmacology of buprenorphine. It is a partial μ receptor agonist with a low intrinsic activity at the receptor site. Clinically this gives it a “ceiling effect”: its opioid agonist effects plateau at higher doses (hence the low risk of overdose). Buprenorphine attaches tightly to opioid receptors and dissociates slowly from them, giving it a 2- or 3-day duration of action. Because of its slow onset of action, opioid-dependent patients do not experience sedation or euphoria when taking the appropriate dose. Its high receptor affinity causes it to displace other opioids from endorphin receptors,32 triggering withdrawal in patients who are physically dependent on opioids.

View this table:
  • View inline
  • View popup
Table 3.

Summary of buprenorphine pharmacology

Buprenorphine is available as a combined product of buprenorphine and naloxone in a 4:1 ratio. Unlike methadone, that is dispensed in 100 mL of orange juice, buprenorphine is a tablet that can be easily crushed and injected. Naloxone, an opioid antagonist, has poor oral bioavailability, but will precipitate withdrawal in opioid-dependent patients if used intravenously,33 thereby discouraging intravenous abuse. Naloxone does not interfere with the pharmacokinetics or effectiveness of buprenorphine when the combination formulation is taken sublingually.10,34,35

Benefits and adverse effects

Buprenorphine has side effects similar to other opioids, including sedation, constipation, and nausea. Buprenorphine has several advantages over methadone besides a lower overdose risk. It does not prolong the QT interval36,37 and it is less likely to cause erectile dysfunction.38,39 Buprenorphine patients perform better than methadone-maintained patients on cognitive and psychomotor tests,40,41 and the cognitive effects of concurrent benzodiazepine use are less pronounced than they are with methadone.42

All buprenorphine-exposed neonates need to be observed for neonatal abstinence syndrome. Research studies have demonstrated that exposure to buprenorphine in utero is associated with milder and shorter neonatal withdrawal than seen with methadone maintenance treatment.43–45 The safety of buprenorphine during lactation remains uncertain. Buprenorphine has been detected in breast milk in amounts similar to maternal serum levels; however, as buprenorphine undergoes a high first-pass metabolism and has poor oral bioavailability, infants are exposed to substantially lower amounts through breastfeeding. Furthermore, neonatal abstinence syndrome presentation and management are not altered by breastfeeding. Women need to consider the benefits of breastfeeding for their babies against the potential risk of exposure to a small proportion of buprenorphine in breast milk.45,46

Special considerations

Availability

Table 4 lists the criteria for buprenorphine coverage under provincial drug plans. Currently only Ontario and Quebec provide coverage for family physicians’ prescriptions.

View this table:
  • View inline
  • View popup
Table 4.

Buprenorphine coverage under different provincial drug plans

Training

Physicians prescribing buprenorphine can be trained in its use with a workshop or online course (Box 1). While the drug itself is safe and easy to prescribe, training is recommended because most family physicians are unfamiliar with the components of opioid agonist treatment (eg, take-home doses, regular urine drug screens).

Box 1.

Resources for physicians

Training courses

  • Online course: Suboxone Training Program, Schering-Plough (www.suboxonecme.ca)

  • Online and in-person: Centre for Addiction and Mental Health in Toronto, Ont (www.camh.net)

Clinical guidelines available on the Internet

Canada

  • Quebec: Collège des médecins du Québec, Ordre des pharmaciens du Québec. La buprénorphine dans le traitement de la dépendance aux opioïdes. Lignes directrices. Montreal, QC: Ordre des pharmaciens du Québec; 2009. (www.opq.org)

  • Ontario: Centre for Addiction and Mental Health guidelines are in progress. (www.camh.net)

United Kingdom

  • Ford C, Morton S, Lintzeris N, Bury J, Gerada C. Guidance for the use of buprenorphine for the treatment of opioid dependence in primary care. 2nd ed. London, UK: RCGP Drug and Alcohol Misuse Training Programme; 2004. (www.rcgp.org.uk/pdf/drug_buprenorphine.pdf)

Australia

  • Lintzeris N, Clark N, Muhleisen P, Ritter A, Ali R, Bell J, et al. Clinical guidelines: buprenorphine treatment of heroin dependence. Canberra, Australia: Commonwealth of Australia; 2006. (www.health.vic.gov.au/dpu/downloads/bupguide)

United States

  • Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. A treatment improvement protocol (TIP), series 40. Rockville, MD: US Department of Health and Human Services; 2004. (www.samhsa.gov)

Physician support and advice

  • Clinicians can contact the Toronto Centre for Substance Use in Pregnancy at St Joseph’s Health Centre with additional questions regarding the use of buprenorphine during pregnancy (telephone 416 530-6860)

  • Physician Clinical Support System (www.pcssmentor.org)

Dose titration

If patients take buprenorphine while they have another opioid in their systems, they might experience withdrawal. This occurs as a result of the buprenorphine displacing the original opioid from the opioid receptors, triggering acute withdrawal in patients who are physically dependent. Symptoms of precipitated withdrawal peak within 1.5 to 3 hours of the buprenorphine dose, and can take up to 12 hours to resolve.29,47 This can be prevented by administering the first buprenorphine dose after the patient’s last opioid dose has worn off, when the patient is in moderate opioid withdrawal (Box 2). Physicians who are unfamiliar with opioid withdrawal might consider using the Clinical Opiate Withdrawal Scale (COWS) to help them decide when to give the first dose of buprenorphine (www.csam-asam.org).48 The initial buprenorphine dose is 2 to 4 mg. The first day’s total dose should be no more than 8 mg, with daily increases of 2 to 4 mg as necessary.46 The optimal dose relieves cravings and symptoms of withdrawal for a full 24 hours, without causing sedation. The usual therapeutic range is 8 to 16 mg daily, to a maximum of 24 mg a day.46 While induction in the physician’s office is usually recommended, preliminary research has found that home induction is safe and might be more practical and acceptable to patients.49 If home induction is used, patients should be advised to take the first dose only when they are in withdrawal and to call the doctor’s office if they have concerns. It is probably best to do home inductions earlier on in the week so that patients can then be reassessed in a day or two in the office for dose adjustments and also so that the office is open for any patient queries. Patients should be warned that they might experience some sedation during the titration phase and they should avoid driving or taking sedating medications.

Box 2.

Initial buprenorphine titration

Before starting

Before the first dose of buprenorphine, the patient needs to be in opioid withdrawal. The timing of the last opioid dose before the office visit should be as follows:

  • Short-acting opioids—12 h or more

  • Longer-acting opioids—24 h or more

  • Methadone—36 h to 3 d

Initial dose

Dispense 2–4 mg only if the patient has symptoms of withdrawal

  • 2 mg if at higher risk (eg, older, lower tolerance, taking benzodiazepines)

  • 4 mg for lower-risk patients

Observe for 2 h, then dispense according to symptoms:

  • Withdrawal symptoms resolved

    • -Discharge with prescription for 2–4 mg/d, depending on initial dose

  • Withdrawal symptoms only slightly better

    • -Dispense another 4 mg

    • -Discharge with prescription (8–12 mg/d, dispensed daily)

    • -Follow up in 1–4 d to reassess dose

  • Withdrawal symptoms substantially worse (precipitated withdrawal)

    • -Symptomatic treatment (eg, dimenhydrinate, naproxen)

    • -Repeat induction the next day

Discharge and follow-up

  • Advise patient to avoid alcohol or sedating drugs and to avoid driving until tolerant to dose

  • If possible, schedule a follow-up visit 1–4 d after start of induction to reassess dose

  • For the first week, provide telephone or in-person access to a nurse or physician for dose adjustments and support

    • -Increase dose by 4–8 mg for withdrawal symptoms and cravings

    • -Optimal dose relieves cravings and withdrawal for 24 h

  • Usual range is 8–16 mg/d; maximum daily dose is 24 mg

Case continued

Mr H. takes his last dose of oxycodone on Sunday morning and shows up at his family physician’s office on Monday morning reporting diarrhea, nausea, myalgia, and cravings. He is given a prescription for 1, 8-mg buprenorphine tablet and instructed to return to the office with the medication. He is given half a tablet (4 mg) sublingually in the office and is reassessed 2 hours later. He reports feeling better but still has some withdrawal symptoms. He is given another 4-mg sublingual dose to bring his total daily dose to 8 mg. He is given a prescription for 8 mg sublingually, once daily for the next 2 mornings, to be observed in the pharmacy. At his follow-up visit on Thursday, he describes withdrawal symptoms 12 hours after taking each dose. His dosage is increased to 12-mg sublingually, once daily, and a follow-up visit is booked for the following Wednesday. At that visit, he states that the 12-mg dose relieves withdrawal symptoms for 24 hours. He is given a prescription for daily observed dosing with a Sunday take-home dose.

Less-than-daily dosing

Less-than-daily dosing (eg, double the daily dose given every 2 days), which is outlined in Box 3, is as effective as daily dosing in reducing opioid use.50 It is preferred by patients who are not eligible for take-home doses, as they must otherwise visit the pharmacy daily.51–53

Opioid detoxification with buprenorphine

Buprenorphine detoxification (Box 4) is more effective than nonopioid treatments for relieving opioid withdrawal symptoms54–56 and retaining patients in treatment.50,57,58 However, it is less effective than buprenorphine maintenance treatment.59–61 Detoxification might be considered for patients with good prognostic factors (Table 2) who do not need or want maintenance treatment. Detoxification should in most cases be immediately followed by an addiction treatment program, as by itself it is unlikely to be effective. Patients should be warned that they quickly lose tolerance with abstinence and can overdose if they relapse to their previous dose.

Box 3.

Less-than-daily dosing

Prescribe

Prescribe less-than-daily dosing after 1 mo on daily dose and 2 wk on stable dose

Revert

Revert to daily dosing if patient experiences considerable sedation with higher dose or uncomfortable withdrawal symptoms despite maximum dose (32 mg)

Examples

Four times/wk: eg, convert 8 mg/d to 16 mg on Monday, 16 mg on Wednesday and Friday, and 8 mg on Sunday Three times/wk: eg, convert 8 mg/d to 16 mg on Monday, 16 mg on Wednesday, and 24 mg on Friday

Tapering

Patients who have been on a stable buprenorphine dose and are doing well might choose to taper off buprenorphine for financial or personal reasons (Box 4). Tapering has a high risk of relapse and works best for patients with a short history of addiction and a strong support network, who have not used unauthorized drugs for months and who do not have active mood or anxiety disorders. The taper should be put on hold or reversed if the patient relapses or experiences severe withdrawal symptoms or cravings.

Office visits

At each visit, the practitioner should inquire about substance use, mood, and functioning. Physician advice and support should be brief, practical, and solution-focused (Table 6).62

View this table:
  • View inline
  • View popup
Table 6.

Agenda for routine follow-up visits

Take-home doses

Daily observed dispensing of buprenorphine followed by a gradual increase in take-home doses is the recommended policy in Australia, the United Kingdom, and other countries.63–65 Prescribing take-home methadone doses contingent on drug-free urine samples is associated with reductions in opioid, cocaine, and benzodiazepine use.66,67

Box 4.

Protocols for detoxification and tapering

Rapid detoxification

  • Titrate buprenorphine to 8–16 mg over 1–3 d

  • Reduce dose by 2 mg every 1–3 d (inpatients) or 2 mg/wk (outpatients)

  • Treat symptoms: diphenoxylate-atropine, dimenhydrinate, acetaminophen, trazodone

  • Precautions: Always follow with addiction counseling

  • Warn patients that they can overdose if they relapse to their usual opioid dose

Slow outpatient taper

  • Rate: no faster than 2 mg every 2 wk

  • Put taper on hold or reverse if patient experiences severe withdrawal, cravings, relapse, or depression

  • Patient should have input into rate of taper

Take-home doses of buprenorphine should be granted for patients who do not have severe or unstable psychiatric disorders, who can safely store their medication, and who are not currently using other drugs problematically. Take-home doses can also be given if the drug use is occasional and without evidence of harm (eg, weekend cannabis users). The optimal take-home schedule is not known, and schedules should be based on individual clinical considerations. Take-home doses should be prescribed more slowly for patients at higher risk of diversion and intravenous use, such as patients with a history of intravenous drug use or other street or illicit drug use, or patients with evidence of current unstable drug use (Table 7).

View this table:
  • View inline
  • View popup
Table 7.

Suggested take-home dose (carry) schedule

Pharmacy visits can be reduced in such patients through less-than-daily dosing. Patients can be given take-home doses at a faster pace if they are at lower risk of diversion (ie, taking prescription opioids orally from 1 physician only, not abusing street drugs, and not selling or buying their opioids). Daily dispensing might be unnecessary for such patients and could cause them to reject buprenorphine treatment, particularly if they lack transportation or have daily work or family commitments.

In the product monograph, Health Canada recommends that buprenorphine be dispensed daily, except for weekends, for 2 months. Physicians who prescribe take-home doses before 2 months have passed should document their rationale for doing so, as they are prescribing “off label.”

Urine drug testing

Urine drug screening (UDS) is recommended at each office visit, as UDS combined with self-report is more accurate than either method alone.68 Infrequent UDS will fail to detect many cases of substance use, particularly if the use is less than daily.69 Granting take-home doses in response to negative UDS results (contingency management) is effective in reducing drug use.70

Case continued

Two months later, Mr H. is doing well on 12 mg of sublingual buprenorphine daily and results of his regular UDS have been negative for any unprescribed substances. He has discontinued all use of oxycodone. His mood is improved and, while he still has chronic low back pain, he feels that his pain is much better now that he has discontinued the oxycodone. Because he is now clinically stable and no longer using drugs problematically, his physician prescribes take-home doses for Monday and Thursday as well as Sunday.

Conclusion

Buprenorphine is a safe and effective treatment for primary care patients who are addicted to prescription opioids. Family physicians can safely prescribe buprenorphine in an office-based setting. Patients who fail to respond to buprenorphine treatment should be referred for methadone treatment.

Notes

KEY POINTS

North America has witnessed a marked increase in prescription opioid misuse and addiction in the past 10 years, accompanied by increases in overdose deaths. These increases parallel the rise in the use of controlled-release opioids for chronic pain. Despite the great need for opioid addiction treatment, access to methadone treatment is limited. Treatment access would expand considerably if family physicians began to prescribe buprenorphine, a safe and effective alternative to methadone. This article reviews the use of buprenorphine in primary care.

POINTS DE REPÈRE

Au cours des 10 dernières années, l’Amérique du Nord a connu une forte augmentation d’abus et de dépendance aux opiacés sous ordonnance ainsi qu’une augmentation des décès par surdose. Ces augmentations ont évolué parallèlement à l’accroissement de l’usage d’opiacés à libération contrôlée pour soulager la douleur chronique. Même s’il y a un grand besoin de traitement de la dépendance aux opiacés, l’accès au traitement par la méthadone est limité. L’accès au traitement serait considérablement meilleur si les médecins de famille décidaient de prescrire de la buprénorphine, une alternative à la méthadone qui est sécuritaire et efficace. Cet article fait le point sur l’usage de la buprénorphine en médecine de première ligne.

Footnotes

  • This article has been peer reviewed.

  • Cet article a fait l’objet d’une révision par des pairs.

  • This article is eligible for Mainpro-M1 credits. To earn credits, go to www.cfp.ca and click on the Mainpro link.

  • Contributors

    All authors contributed to concept and design of the study; data gathering, analysis, and interpretation; and preparing the manuscript for submission.

  • Competing interests

    Drs Srivastava and Kahan have received a grant from Schering-Plough for educational research on Suboxone. Dr Kahan received an honorarium from Schering-Plough to prepare a brief for Health Canada. Dr Ordean received funding from the National Institute on Drug Abuse to research opioid dependence in pregnancy (grant R01 DA015741).

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Novak S,
    2. Nemeth WC,
    3. Lawson KA
    . Trends in medical use and abuse of sustained-release opioid analgesics: a revisit. Pain Med 2004;5(1):59-65.
    OpenUrlCrossRefPubMed
  2. 2.
    1. Sproule B,
    2. Brands B,
    3. Li S,
    4. Catz-Biro L
    . Changing patterns in opioid addiction: characterizing users of oxycodone and other opioids. Can Fam Physician 2009;55:68-9.e1-5. Available from: www.cfp.ca/cgi/reprint/55/1/68. Accessed 2011 Jan 27.
    OpenUrl
  3. 3.↵
    1. Fischer B,
    2. Rehm J,
    3. Patra J,
    4. Cruz MF
    . Changes in illicit opioid use across Canada. CMAJ 2006;175(11):1385-7.
    OpenUrlFREE Full Text
  4. 4.↵
    1. Dasgupta N,
    2. Kramer ED,
    3. Zalman MA,
    4. Carino S Jr.,
    5. Smith MY,
    6. Haddox JD,
    7. et al
    . Association between non-medical and prescriptive usage of opioids. Drug Alcohol Depend 2006;82(2):135-42. Epub 2005 Oct 19.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Popova S,
    2. Rehm J,
    3. Fischer B
    . An overview of illegal opioid use and health services utilization in Canada. Public Health 2006;120(4):320-8. Epub 2006 Feb 14.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Auriacombe M,
    2. Fatséas M,
    3. Dubernet J,
    4. Daulouède JP,
    5. Tignol J
    . French field experience with buprenorphine. Am J Addict 2004;13(Suppl 1):S17-28.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Mintzer IL,
    2. Eisenberg M,
    3. Terra M,
    4. MacVane C,
    5. Himmelstein DU,
    6. Woolhandler S
    . Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med 2007;5(2):146-50.
    OpenUrlAbstract/FREE Full Text
  8. 8.
    1. Amass L,
    2. Ling W,
    3. Freese TE,
    4. Reiber C,
    5. Annon JJ,
    6. Cohen AJ,
    7. et al
    . Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict 2004;13(Suppl 1):S42-66.
    OpenUrlCrossRefPubMed
  9. 9.
    1. Fiellin DA,
    2. Pantalon MV,
    3. Pakes JP,
    4. O’Connor PG,
    5. Chawarski M,
    6. Schottenfeld RS
    . Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse 2002;28(2):231-41.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Fudala PJ,
    2. Bridge TP,
    3. Herbert S,
    4. Williford WO,
    5. Chiang CN,
    6. Jones K,
    7. et al
    . Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003;349(10):949-58.
    OpenUrlCrossRefPubMed
  11. 11.
    1. Ortner R,
    2. Jagsch R,
    3. Schindler SD,
    4. Primorac A,
    5. Fischer G,
    6. General Practitioner Addiction Team
    . Buprenorphine maintenance: office-based treatment with addiction clinic support. Eur Addict Res 2004;10(3):105-11.
    OpenUrlPubMed
  12. 12.
    1. O’Connor PG,
    2. Oliveto AH,
    3. Shi JM,
    4. Triffleman EG,
    5. Carroll KM,
    6. Kosten TR,
    7. et al
    . A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med 1998;105(2):100-5.
    OpenUrlCrossRefPubMed
  13. 13.
    1. O’Connor PG,
    2. Oliveto AH,
    3. Shi JM,
    4. Triffleman E,
    5. Carroll KM,
    6. Kosten TR,
    7. et al
    . A pilot study of primary-care-based buprenorphine maintenance for heroin dependence. Am J Drug Alcohol Abuse 1996;22(4):523-31.
    OpenUrlPubMed
  14. 14.
    1. Lintzeris N,
    2. Ritter A,
    3. Panjari M,
    4. Clark N,
    5. Kutin J,
    6. Bammer G
    . Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial. Am J Addict 2004;13(Suppl 1):S29-41.
    OpenUrlCrossRefPubMed
  15. 15.
    1. Lintzeris N,
    2. Ritter A,
    3. Dunlop A,
    4. Muhleisen P
    . Training primary health care professionals to provide buprenorphine and LAAM treatment. Subst Abus 2002;23(4):245-54.
    OpenUrlPubMed
  16. 16.
    1. Vignau J,
    2. Brunelle E
    . Differences between general practitioner- and addiction centre-prescribed buprenorphine substitution therapy in France. Preliminary results. Eur Addict Res 1998;4(Suppl 1):24-8.
    OpenUrlPubMed
  17. 17.
    1. Gibson AE,
    2. Doran CM,
    3. Bell JR,
    4. Ryan A,
    5. Lintzeris N
    . A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial. Med J Aust 2003;179(1):38-42.
    OpenUrlPubMed
  18. 18.↵
    1. Connock M,
    2. Juarez-Garcia A,
    3. Jowett S,
    4. Frew E,
    5. Liu Z,
    6. Taylor RJ,
    7. et al
    . Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007;11(9):1-171, iii-iv.
    OpenUrlPubMed
  19. 19.
    1. Simoens S,
    2. Matheson C,
    3. Bond C,
    4. Inkster K,
    5. Ludbrook A
    . The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. Br J Gen Pract 2005;55(511):139-46.
    OpenUrlAbstract/FREE Full Text
  20. 20.
    1. Amato L,
    2. Davoli M,
    3. Perucci CA,
    4. Ferri M,
    5. Faggiano F,
    6. Mattick RP
    . An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005;28(4):321-9.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Alford DP,
    2. LaBelle CT,
    3. Richardson JM,
    4. O’Connell JJ,
    5. Hohl CA,
    6. Cheng DM,
    7. et al
    . Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med 2007;22(2):171-6.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Doran CM,
    2. Shanahan M,
    3. Mattick RP,
    4. Ali R,
    5. White J,
    6. Bell J,
    7. et al
    . Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend 2003;71(3):295-302.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Mattick RP,
    2. Kimber J,
    3. Breen C,
    4. Davoli M
    . Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2003;(2):CD002207. Update in: Database Syst Rev 2004;(3):CD002207.
  24. 24.↵
    1. Moore BA,
    2. Fiellin DA,
    3. Barry DT,
    4. Sullivan LE,
    5. Chawarski MC,
    6. O’Connor PG,
    7. et al
    . Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Intern Med 2007;22(4):527-30.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Borron SW,
    2. Monier C,
    3. Risède P,
    4. Baud FJ
    . Flunitrazepam variably alters morphine, buprenorphine, and methadone lethality in the rat. Hum Exp Toxicol 2002;21(11):599-605.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Boyd J,
    2. Randell T,
    3. Luurila H,
    4. Kuisma M
    . Serious overdoses involving buprenorphine in Helsinki. Acta Anaesthesiol Scand 2003;47(8):1031-3.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Auriacombe M,
    2. Franques P,
    3. Tignol J
    . Deaths attributable to methadone vs buprenorphine in France. JAMA 2001;285(1):45.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Kakko J,
    2. Grönbladh L,
    3. Svanborg KD,
    4. von Wachenfeldt J,
    5. Rück C,
    6. Rawlings B,
    7. et al
    . A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 2007;164(5):797-803.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Lintzeris N,
    2. Muhleisen P,
    3. Ritter A
    . Clinical guidelines: buprenorphine treatment of heroin dependence. Canberra, Australia: National Expert Advisory Committee on Illicit Drugs; 2001.
  30. 30.↵
    1. Johnson RE,
    2. Jones HE,
    3. Fischer G
    . Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003;70(2 Suppl):S87-101.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Lacroix I,
    2. Berrebi A,
    3. Chaumerliac C,
    4. Lapeyre-Mestre M,
    5. Montastruc JL,
    6. Damase-Michel C
    . Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. Addiction 2004;99(2):209-14.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Schuh KJ,
    2. Walsh SL,
    3. Stitzer ML
    . Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. Psychopharmacology (Berl) 1999;145(2):162-74.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Johnson RE,
    2. Strain EC,
    3. Amass L
    . Buprenorphine: how to use it right. Drug Alcohol Depend 2003;70(2 Suppl):S59-77.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Chiang CN,
    2. Hawks RL
    . Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend 2003;70(2 Suppl):S39-47.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Johnson RE,
    2. McCagh JC
    . Buprenorphine and naloxone for heroin dependence. Curr Psychiatry Rep 2000;2(6):519-26.
    OpenUrlPubMed
  36. 36.↵
    1. Fanoe S,
    2. Hvidt C,
    3. Ege P,
    4. Jensen GB
    . Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart 2007;93(9):1051-5. Epub 2007 Mar 7.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Wedam EF,
    2. Bigelow GE,
    3. Johnson RE,
    4. Nuzzo PA,
    5. Haigney MC
    . QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007;167(22):2469-75.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Hallinan R,
    2. Byrne A,
    3. Agho K,
    4. McMahon C,
    5. Tynan P,
    6. Attia J
    . Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. J Sex Med 2008;5(3):684-92. Epub 2007 Dec 18.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Hallinan R,
    2. Byrne A,
    3. Agho K,
    4. McMahon CG,
    5. Tynan P,
    6. Attia J
    . Hypogonadism in men receiving methadone and buprenorphine maintenance treatment. Int J Androl 2007;32(2):131-9. Epub 2007 Oct 30.
    OpenUrlPubMed
  40. 40.↵
    1. Pirastu R,
    2. Fais R,
    3. Messina M,
    4. Bini V,
    5. Spiga S,
    6. Falconieri D,
    7. et al
    . Impaired decision-making in opiate-dependent subjects: effect of pharmacological therapies. Drug Alcohol Depend 2006;83(2):163-8. Epub 2005 Dec 15.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Rapeli P,
    2. Fabritius C,
    3. Alho H,
    4. Salaspuro M,
    5. Wahlbeck K,
    6. Kalska H
    . Methadone vs buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. BMC Clin Pharmacol 2007;7:5.
    OpenUrlPubMed
  42. 42.↵
    1. Lintzeris N,
    2. Mitchell TB,
    3. Bond A,
    4. Nestor L,
    5. Strang J
    . Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients. J Clin Psychopharmacol 2006;26(3):274-83.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Jones HE,
    2. Johnson RE,
    3. Jasinski DR,
    4. O’Grady KE,
    5. Chisholm CA,
    6. Choo RE,
    7. et al
    . Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005;79(1):1-10.
    OpenUrlCrossRefPubMed
  44. 44.
    1. Schindler SD,
    2. Eder H,
    3. Ortner R,
    4. Rohrmeister K,
    5. Langer M,
    6. Fischer G
    . Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction 2003;98(1):103-10.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Marquet P,
    2. Chevrel J,
    3. Lavignasse P,
    4. Merle L,
    5. Lachatre G
    . Buprenorphine withdrawal syndrome in a newborn. Clin Pharmacol Ther 1997;62(5):569-71.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Center for Substance Abuse Treatment
    . Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP), series 40. Rockville, MD: US Department of Health and Human Services; 2004. DHHS Publication No. (SMA) 04-3939.
  47. 47.↵
    1. Jones HE
    . Practical considerations for clinical use of buprenorphine. Sci Pract Perspect 2004;2(2):4-20.
    OpenUrlPubMed
  48. 48.↵
    1. Wesson DR,
    2. Ling WJ
    . The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 2003;35(2):253-9.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Lee JD,
    2. Grossman E,
    3. DiRocco D,
    4. Gourevitch MN
    . Home buprenorphine/naloxone induction in primary care. J Gen Intern Med 2009;24(2):226-32. Epub 2008 Dec 17.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Caldiero RM,
    2. Parran TV Jr.,
    3. Adelman CL,
    4. Piche B
    . Inpatient initiation of buprenorphine maintenance vs detoxification: can retention of opioid-dependent patients in outpatient counseling be improved? Am J Addict 2006;15(1):1-7.
    OpenUrlPubMed
  51. 51.↵
    1. Amass L,
    2. Bickel WK,
    3. Higgins ST,
    4. Badger GJ
    . Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sci 1994;54(17):1215-28.
    OpenUrlCrossRefPubMed
  52. 52.
    1. Amass L,
    2. Bickel WK,
    3. Crean JP,
    4. Blake J,
    5. Higgins ST
    . Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology (Berl) 1998;136(3):217-25.
    OpenUrlCrossRefPubMed
  53. 53.↵
    1. Amass L,
    2. Kamien JB,
    3. Mikulich SK
    . Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend 2001;61(2):173-81.
    OpenUrlCrossRefPubMed
  54. 54.↵
    1. Amato L,
    2. Davoli M,
    3. Ferri M,
    4. Gowing L,
    5. Perucci CA
    . Effectiveness of interventions on opiate withdrawal treatment: an overview of systematic reviews. Drug Alcohol Depend 2004;73(3):219-26.
    OpenUrlCrossRefPubMed
  55. 55.
    1. Gowing L,
    2. Ali R,
    3. White J
    . Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2002;(2):CD002025.
  56. 56.↵
    1. Gowing L,
    2. Ali R,
    3. White J
    . Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2006;(2):CD002025.
  57. 57.↵
    1. Marsch LA,
    2. Bickel WK,
    3. Badger GJ,
    4. Stothart ME,
    5. Quesnel KJ,
    6. Stanger C,
    7. et al
    . Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry 2005;62(10):1157-64.
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. Brigham GS,
    2. Amass L,
    3. Winhusen T,
    4. Harrer JM,
    5. Pelt A
    . Using buprenorphine short-term taper to facilitate early treatment engagement. J Subst Abuse Treat 2007;32(4):349-56.
    OpenUrlPubMed
  59. 59.↵
    1. Kornør H,
    2. Waal H,
    3. Ali RL
    . Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling. Drug Alcohol Rev 2006;25(2):123-30.
    OpenUrlPubMed
  60. 60.
    1. Kornør H,
    2. Waal H,
    3. Sandvik L
    . Time-limited buprenorphine replacement therapy for opioid dependence: 2-year follow-up outcomes in relation to programme completion and current agonist therapy status. Drug Alcohol Rev 2007;26(2):135-41.
    OpenUrlCrossRefPubMed
  61. 61.↵
    1. Horspool MJ,
    2. Seivewright N,
    3. Armitage CJ,
    4. Mathers N
    . Post-treatment outcomes of buprenorphine detoxification in community settings: a systematic review. Eur Addict Res 2008;14(4):179-85. Epub 2008 Jun 27.
    OpenUrlPubMed
  62. 62.↵
    1. Fiellin DA,
    2. Pantalon MV,
    3. Chawarski MC,
    4. Moore BA,
    5. Sullivan LE,
    6. O’Connor PG,
    7. et al
    . Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med 2006;355(4):365-74.
    OpenUrlCrossRefPubMed
  63. 63.↵
    1. Vignau J,
    2. Duhamel A,
    3. Catteau J,
    4. Legal G,
    5. Pho AH,
    6. Grailles I,
    7. et al
    . Practice-based buprenorphine maintenance treatment (BMT): how do French health-care providers manage the opiate-addicted patients? J Subst Abuse Treat 2001;21(3):135-44.
    OpenUrlPubMed
  64. 64.
    1. Ford C,
    2. Morton S,
    3. Lintzeris N,
    4. Bury J,
    5. Gerada C
    . Guidance for the use of buprenorphine for the treatment of opioid dependence in primary care. 2nd ed. London, UK: RCGP Drug and Alcohol Misuse Training Programme; 2004.
  65. 65.↵
    1. Lintzeris N,
    2. Clark N,
    3. Muhleisen P,
    4. Ritter A,
    5. Ali R,
    6. Bell J,
    7. et al
    . Clinical guidelines: buprenorphine treatment of heroin dependence. Canberra, Australia: Commonwealth of Australia; 2006.
  66. 66.↵
    1. Chutuape MA,
    2. Silverman K,
    3. Stitzer ML
    . Effects of urine testing frequency on outcome in a methadone take-home contingency program. Drug Alcohol Depend 2001;62(1):69-76.
    OpenUrlCrossRefPubMed
  67. 67.↵
    1. Preston KL,
    2. Umbricht A,
    3. Epstein DH
    . Abstinence reinforcement maintenance contingency and one-year follow-up. Drug Alcohol Depend 2002;67(2):125-37.
    OpenUrlCrossRefPubMed
  68. 68.↵
    1. Bell J,
    2. Shanahan M,
    3. Mutch C,
    4. Rea F,
    5. Ryan A,
    6. Batey R,
    7. et al
    . A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction 2007;102(12):1899-907.
    OpenUrlCrossRefPubMed
  69. 69.↵
    1. Perrone J,
    2. De Roos F,
    3. Jayaraman S,
    4. Hollander JE
    . Drug screening versus history in detection of substance use in ED psychiatric patients. Am J Emerg Med 2001;19(1):49-51.
    OpenUrlCrossRefPubMed
  70. 70.↵
    1. Srivastava A,
    2. Kahan M
    . Buprenorphine: a potential new treatment option for opioid dependence. CMAJ 2006;174(13):1835.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Canadian Family Physician: 57 (3)
Canadian Family Physician
Vol. 57, Issue 3
1 Mar 2011
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Buprenorphine
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Buprenorphine
Meldon Kahan, Anita Srivastava, Alice Ordean, Sharon Cirone
Canadian Family Physician Mar 2011, 57 (3) 281-289;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Buprenorphine
Meldon Kahan, Anita Srivastava, Alice Ordean, Sharon Cirone
Canadian Family Physician Mar 2011, 57 (3) 281-289;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Quality of evidence
    • Clinical features of prescription opioid addiction
    • Case
    • Role of buprenorphine in primary care
    • Case continued
    • Indications for buprenorphine treatment
    • Case continued
    • Pharmacology
    • Benefits and adverse effects
    • Special considerations
    • Dose titration
    • Case continued
    • Less-than-daily dosing
    • Opioid detoxification with buprenorphine
    • Tapering
    • Office visits
    • Take-home doses
    • Urine drug testing
    • Case continued
    • Conclusion
    • Notes
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Sleep disordered breathing in patients receiving therapy with buprenorphine/naloxone
  • Mise a jour sur l'utilisation clinique de la buprenorphine: pour les troubles relies aux opioides
  • Update on the clinical use of buprenorphine: In opioid-related disorders
  • Lignes directrices canadiennes sur l'utilisation securitaire et efficace des opioides pour la douleur chronique non cancereuse: Resume clinique pour les medecins de famille. Partie 2: populations particulieres
  • Canadian guideline for safe and effective use of opioids for chronic noncancer pain: Clinical summary for family physicians. Part 2: special populations
  • Google Scholar

More in this TOC Section

Practice

  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
  • Spontaneous pneumothorax in children
Show more Practice

Clinical Review

  • Parkinson disease primer, part 1: diagnosis
  • Prescribing for common complications of spinal cord injury
  • Individualized antidepressant therapy in patients with major depressive disorder
Show more Clinical Review

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2023 by The College of Family Physicians of Canada

Powered by HighWire